SCHEMBL3265679

SCHEMBL3265679

NC(=O)COC(=O)NCC1CCN(c2cc(C(F)(F)F)ccn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 2/20 0.50
FFAR4 Q5NUL3 1/20 0.49
ADRB1 P08588 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
FFAR1 O14842 1/20 0.46
CETP P11597 1/20 0.45
MAPT P10636 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43
DPP4 P27487 1/20 0.43
DPP7 Q9UHL4 1/20 0.43
ACACB O00763 1/20 0.43
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
LCAT P04180 2/20 0.41
CKS1B P61024 2/20 0.41
SKP1 P63208 2/20 0.41
SKP2 Q13309 2/20 0.41
LDHA P00338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265682 0.91 CHRM4 (0.58) CHRM4FFAR4ADRB1HRH3FFAR1
SCHEMBL3265636 0.85 KDM4E (0.58) CHRM4CETPKDM4EALDH1A1CHRM2
SCHEMBL1729388 0.83 FFAR4 (0.59) CHRM4FFAR4ADRB1HRH3FFAR1
SCHEMBL3265549 0.80 CHRM4 (0.50) CHRM4ADRB1CETPKDM4EDPP4
SCHEMBL3270009 0.79 KDM4E (0.51) KDM4EALDH1A1
SCHEMBL3269081 0.77 CHRM4 (0.57) CHRM4KDM4ECHRM2CHRM1CHRM3
SCHEMBL1728821 0.76 CHRM4 (0.68) CHRM4FFAR4ADRB1HRH3FFAR1
SCHEMBL3268917 0.76 CKS1B (0.47) DPP4ACACBCKS1BSKP1SKP2
SCHEMBL3265671 0.76 DEGS1 (0.49) MAPTKDM4ECKS1BSKP1SKP2
SCHEMBL3266209 0.76 CKS1B (0.44) HRH3CETPKDM4EACACBCKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CHRM4 243/4885FFAR4 3684/4885ADRB1 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.